Friday November 27 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

BioPortfolio's Approved Drugs Database

Rapaflo

Silodosin

Download PDF containing detailed information.PDF Version

Image Results

Loading...

Press Releases About Rapaflo:

 BioPortfolio Logo
Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook 29th July, 2009 Watson Pharmaceuticals, Inc.
Generic Segment Information Three Months Ended Six Months Ended June 30, June 30,
Watson Pharmaceuticals Reports First Quarter 2009 Results; Raises 2009 Outlook 30th April, 2009 Watson Pharmaceuticals, Inc.
Record Total Net Revenue of $667 Million; GAAP EPS $0.43; Adjusted EPS $0.58 CORONA, Calif., April 30 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty
Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 19th February, 2009 Watson Pharmaceuticals, Inc.
CORONA, Calif., Feb. 19 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leader in generic and specialty branded pharmaceuticals, today reported financial results for its

This page has been viewed 24 times Browse BioPortfolio's InDepth service - alphabetically: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z or by Most Publications, recently searched for, or most viewed.

Search for Rapaflo across BioPortfolio, or for Rapaflo Research Reports
Wikipedia excerpt, where present, licenced under the GNU Free Documentation License. Resources from the NCBI applied. Selected MeSH subject headings created and maintained by the US NLM are used in conjunction with additional keywords. 2006-2008 MeSH. Thumbshots from Thumbshots.org

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.